BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Venetsanaki V, Polyzos SA. Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives. Curr Vasc Pharmacol. 2019;17:546-555. [PMID: 29992886 DOI: 10.2174/1570161116666180711121949] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Kim SJ, Miller B, Kumagai H, Yen K, Cohen P. MOTS-c: an equal opportunity insulin sensitizer. J Mol Med (Berl) 2019;97:487-90. [PMID: 30788534 DOI: 10.1007/s00109-019-01758-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
2 Robeva R, Mladenović D, Vesković M, Hrnčić D, Bjekić-Macut J, Stanojlović O, Livadas S, Yildiz BO, Macut D. The interplay between metabolic dysregulations and non-alcoholic fatty liver disease in women after menopause. Maturitas 2021;151:22-30. [PMID: 34446275 DOI: 10.1016/j.maturitas.2021.06.012] [Reference Citation Analysis]
3 Radulescu A, Dugan AJ, Killian M, Attia SL, Mouzaki M, Fuchs GJ, Kohli R, Bada H, Kern PA, Softic S. Stratification by obesity class, rather than age, can identify a higher percent of children at risk for non-alcoholic fatty liver disease and metabolic dysfunction. Pediatr Obes 2021;:e12862. [PMID: 34662928 DOI: 10.1111/ijpo.12862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cataldi M, Citro V, Resnati C, Manco F, Tarantino G. New Avenues for Treatment and Prevention of Drug-Induced Steatosis and Steatohepatitis: Much More Than Antioxidants. Adv Ther 2021;38:2094-113. [PMID: 33761100 DOI: 10.1007/s12325-021-01669-y] [Reference Citation Analysis]
5 Ghoneim S, Dhorepatil A, Shah AR, Ram G, Ahmad S, Kim C, Asaad I. Non-alcoholic steatohepatitis and the risk of myocardial infarction: A population-based national study. World J Hepatol 2020; 12(7): 378-388 [PMID: 32821336 DOI: 10.4254/wjh.v12.i7.378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Shin Y, Lee M, Lee D, Jang J, Shin SS, Yoon M. Fenofibrate Regulates Visceral Obesity and Nonalcoholic Steatohepatitis in Obese Female Ovariectomized C57BL/6J Mice. Int J Mol Sci 2021;22:3675. [PMID: 33916086 DOI: 10.3390/ijms22073675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lonardo A, Arab JP, Arrese M. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. Adv Ther 2021;38:2130-58. [PMID: 33829368 DOI: 10.1007/s12325-021-01690-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Song YJ, Li SR, Li XW, Chen X, Wei ZX, Liu QS, Cheng Y. The Effect of Estrogen Replacement Therapy on Alzheimer's Disease and Parkinson's Disease in Postmenopausal Women: A Meta-Analysis. Front Neurosci 2020;14:157. [PMID: 32210745 DOI: 10.3389/fnins.2020.00157] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
9 El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, Limacher MC, Manson JE, Stefanick ML, Allison MA; American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation 2020;142:e506-32. [PMID: 33251828 DOI: 10.1161/CIR.0000000000000912] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 16.5] [Reference Citation Analysis]
10 Polyzos SA, Goulas A. Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing. Med Hypotheses 2021;146:110379. [PMID: 33208241 DOI: 10.1016/j.mehy.2020.110379] [Reference Citation Analysis]
11 Li Y, Chen Y, Tian X, Zhang S, Jiao J. Comparison of Clinical Characteristics Between Obese and Non-Obese Patients with Nonalcoholic Fatty Liver Disease (NAFLD). Diabetes Metab Syndr Obes 2021;14:2029-39. [PMID: 33986604 DOI: 10.2147/DMSO.S304634] [Reference Citation Analysis]
12 Lei Z, Wu H, Yang Y, Hu Q, Lei Y, Liu W, Nie Y, Yang L, Zhang X, Yang C, Lin T, Tong F, Zhu J, Guo J. Ovariectomy Impaired Hepatic Glucose and Lipid Homeostasis and Altered the Gut Microbiota in Mice With Different Diets. Front Endocrinol (Lausanne) 2021;12:708838. [PMID: 34276568 DOI: 10.3389/fendo.2021.708838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Pafili K, Paschou SA, Armeni E, Polyzos SA, Goulis DG, Lambrinoudaki I. Non-alcoholic fatty liver disease through the female lifespan: the role of sex hormones. J Endocrinol Invest 2022. [PMID: 35303270 DOI: 10.1007/s40618-022-01766-x] [Reference Citation Analysis]
14 Liu PJ, Lou HP, Zhu YN. Identification of Hepatic Steatosis in Premenopausal and Postmenopausal Women Based on Phenotypes Combining Triglyceride Levels and Anthropometric Indices: A Cross-Sectional Study. Diabetes Metab Syndr Obes 2021;14:1339-47. [PMID: 33790601 DOI: 10.2147/DMSO.S302297] [Reference Citation Analysis]
15 Valodara AM, Sr KJ. Sexual Dimorphism in Drug Metabolism and Pharmacokinetics. CDM 2020;20:1154-66. [DOI: 10.2174/1389200220666191021094906] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Di Pasqua LG, Cagna M, Berardo C, Vairetti M, Ferrigno A. Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update. Biomedicines 2022;10:194. [DOI: 10.3390/biomedicines10010194] [Reference Citation Analysis]
17 Anagnostis P, Goulis DG. Menopause and its Cardiometabolic Consequences: Current Perspectives. CVP 2019;17:543-5. [DOI: 10.2174/1570161117999190228123237] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Hur HJ, Jeong YH, Lee SH, Sung MJ. Quercitrin Ameliorates Hyperlipidemia and Hepatic Steatosis in Ovariectomized Mice. Life (Basel) 2020;10:E243. [PMID: 33076582 DOI: 10.3390/life10100243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Park SH, Park YE, Lee J, Choi JH, Heo NY, Park J, Kim TO, Moon YS, Kim HK, Jang HJ, Park HY, Jeong C, Suk KT, Kim DJ. Lack of association between early menopause and non-alcoholic fatty liver disease in postmenopausal women. Climacteric 2020;23:173-7. [DOI: 10.1080/13697137.2019.1650018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Polyzos SA, Anastasilakis AD, Efstathiadou ZA, Yavropoulou MP, Makras P. Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations. Maturitas 2021;147:19-25. [PMID: 33832643 DOI: 10.1016/j.maturitas.2021.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Lonardo A, Mantovani A, Lugari S, Targher G. NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management. Int J Mol Sci. 2019;20. [PMID: 31212642 DOI: 10.3390/ijms20112841] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
22 Salvoza NC, Giraudi PJ, Tiribelli C, Rosso N. Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease. Exploration of Medicine 2020;1:51-74. [DOI: 10.37349/emed.2020.00005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Della Torre S. Beyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology. Cells 2021;10:2502. [PMID: 34572151 DOI: 10.3390/cells10092502] [Reference Citation Analysis]